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This review identiﬁes possible pharmacological targets for inﬂammatory bowel disease (IBD) within the IL-23/IL-17 axis.
Speciﬁcally, there are several targets within the IL-23/IL-17 pathways for potential pharmacological intervention with antibodies
or small molecule inhibitors. These targets include TL1A (tumor necrosis factor-like molecule), DR3 (death receptor 3), IL-23,
IL-17 and the receptors for IL-23 and IL-17. As related to IBD, there are also other novel pharmacological targets. These targets
include inhibiting speciﬁc immunoproteasome subunits, blocking a key enzyme in sphingolipid metabolism (sphingosine kinase),
and modulating NF-κB/STAT3 interactions. Several good approaches exist for pharmacological inhibition of key components
in the IL-23 and IL-17 pathways. These approaches include speciﬁc monoclonal antibodies to TL1A, IL-17 receptor, Fc fusion
proteins, speciﬁc antibodies to IL-17F, and small molecule inhibitors of IL-17 like Vidoﬂudimus. Also, other potential approaches
fortargeteddrugdevelopmentinIBDincludespeciﬁcchemicalinhibitorsofSK,speciﬁcsmallmoleculeinhibitorsdirectedagainst
catalytic subunits of the immunoproteasome, and dual inhibitors of the STAT3 and NF-κB signal transduction systems. In the
future, well-designed preclinical studies are still needed to determine which of these pharmacological approaches will provide
drugs with the best eﬃcacy and safety proﬁles for entrance into clinical trials.
1.Introduction
During the past decade, there has been an expansion in
new scientiﬁc knowledge related to the pathogenesis of
inﬂammatory bowel disease (IBD). This knowledge has
been summarized rather recently in published reviews,
which provided key insights into IBD pathogenesis [1, 2].
Brieﬂy, IBD consists of two distinct diseases, Crohn’s disease
(CD) and ulcerative colitis (UC). CD and UC are thought
to arise due to a combination of genetic variations and
alterations in the bacterial ﬂora, which can subsequently
drive a dysregulated immune response that results in chronic
intestinal inﬂammation [1, 2].
Recent information related to the pathogenesis of IBD
has provided the rationale for new pharmacological ap-
proaches to better treat the intestinal inﬂammation and
related symptoms in patients. Another scientiﬁc review
has succinctly summarized current therapies for IBD:
mesalazine-based drugs, corticosteroids, immunosuppres-
sive drugs (azathioprine/6-mercaptopurine, methotrexate,
cyclosporin, anti-TNF agents), as well as emerging biologic
agents such as antiadhesion and antiintegrin molecules [3].
This review will primarily focus on possible pharma-
cological targets within the IL-23/IL-17 proinﬂammatory
pathway (i.e., IL-23/IL-17 Axis), including some work from
our laboratory [4]. Secondarily, this review will provide
insights into some other novel pharmacological targets, such
as inhibiting speciﬁc immunoproteasome subunits, blocking
a key enzyme in sphingolipid metabolism (sphingosine
kinase), and modulating NF-B/κSTAT3 interactions. Scien-
tiﬁc data supporting these pharmacological targets will be
provided from the published literature [5–12].
There are several targets within the IL-23/IL-17 pathways
for potential pharmacological intervention with antibodies
or small molecule inhibitors. These targets include TL1A,
DR3, IL-23, IL-23R, IL-17, and IL-17R (Figure 1).2 International Journal of Inﬂammation
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Figure 1: This ﬁgure shows relevant cell types, mediators, and potential pharmacological targets associated with IL-23 and IL-17 pathways
(IL-23/IL-17 Axis), which are operative within the context of inﬂammatory bowel disease (IBD). Bacterial ligands (lipopolysaccharide [LPS]
and peptidoglycan [PGN]) bind to their respective toll-like receptors (TLR4 and TLR2) and induce IL-23 release from antigen-presenting
cells (APC’s). IL-23 binds to the IL-23 receptor (IL-23R) to stimulate expansion of Th-17-producing cells, which release IL-17. In addition,
interactions between TL1A (tumor necrosis factor-like molecule) on APC’s and DR3 (death receptor 3) on T lymphocytes induces the
secretion of IL-17. These pathways also promote the secretion other proinﬂammatory cytokines like IL-6 and TNF-α. IL-17 stimulates the
expressionofadhesionmolecules(e.g.,ICAM-1)onendothelialcells,aswellasthereleaseofIL-6andIL-8frommyoﬁbroblastsandepithelial
cells. IL-8 acts as a chemotactic factor for neutrophil inﬂux into the intestine. Inﬁltrating neutrophils release inﬂammatory mediators like
matrix metalloproteinases (MMP’s) and inducible nitric oxide synthase (iNOS). This sequelae of pathogenic events leads to the chronic
inﬂammation and epithelial cell damage associated with IBD.
2. TL1A/DR3
As shown in Figure 1, upstream binding of bacterial derived
ligands such as lipopolysaccharide (LPS) and peptidoglycan
(PGN) to their speciﬁc toll-like receptors (TLR4 and TLR2,
respectively) can induce TL1A (tumor necrosis factor-
like molecule) expression in antigen presenting cells (like
dendritic cells) [13]. Downstream, the interaction of TL1A
with DR3 (death receptor 3) results in the production of IL-
17 from Th17 T lymphocytes [14].
The interaction between this TNF-family member
(TL1A) and its receptor DR3 plays an important role in
autoimmune diseases such as experimental autoimmune
encephalomyelitis (EAE) [15]. More recently, other investi-
gators have published an informative review on the role of
the TL1A-DR3 pathway in the pathogenesis of IBD [14]. Of
note, TL1A expression is increased in the inﬂamed intestinal
tissue of patients with CD [1].
In 2008, Takedatsu and colleagues showed that TL1A
and DR3 expression was upregulated in the gut-associated
lymphoid tissue (GALT) of mice withchronic dextran sulfate
sodium (DSS)-induced colitis [16]. Importantly, from a
pharmacological standpoint, a monoclonal antibody (mAb)
to TL1A eﬀectively attenuated chronic DSS-induced colitis,
as well as T-cell transfer colitis in mice [16]. This antibody
also improved established chronic colitis. The anticolitis
eﬀects were associated with decreases in IFN-γ, IL-17, and
IL-6 production from GALT [16]. These results clearly
established targeting of TL1A, as a rational pharmacological
approach for IBD. More recently, two other research groups
have generated transgenic mice with enhanced expression
of TL1A in T-cells or dendritic cells [17, 18]. These mice
developed predominantly small intestinal pathology, which
was dependent upon DR3, IL-13, and IL-17 [17, 18].
Important studies were then carried out in mice with acute
trinitrobenzenesulfonic acid (TNBS)-induced colitis. These
mice were treated with an antagonistic mAb to TL1A, a
DR3-Fc fusion protein, or an antagonistic mAb to DR3 [17].
Mice treated with anti-TL1A showed a marked improvement
in indices of TNBS-induced colitis. Also, partial protectionInternational Journal of Inﬂammation 3
against this murine colitis was found with the anti-DR3
pharmacological approaches [17]. Taken as a whole, these
results further suggest that targeting of the TL1A-DR3
pathway could be a good pharmacological approach for both
types of human IBD (CD and UC) [17–19].
3.IL-23
As shown in Figure 1, upon stimulation by appropriate
ligands, IL-23 is produced by antigen-presenting cells. After
binding to the appropriate receptor (IL-23R), this cytokine
can stimulate the production of IL-17, TNF-α,a n dI L - 6f r o m
T-cells. Therefore, IL-23 was proposed to play an integral
role in the pathogenesis of IBD [20]. From a potential
therapeutic standpoint, Elson and colleagues created T-cell
transfercolitisinSCIDmicerecipientswithbacterialreactive
Th17 CD4+ T-cells [21]. Treatment of these mice with an
antibody to the p19 subunit of IL-23 both prevented T-cell
transfer colitis and eﬀectively treated established colitis [21].
This is a rather speciﬁc therapeutic approach for treating
IBD, because only the p19 subunit is targeted. This subunit
is endogenous only to IL-23 but is not shared by IL-12, like
the common p40 subunit [21]. An antibody targeting the
common p40 subunit (Ustekinumab) has shown some evi-
dence of eﬃcacy in patients with CD (phase II a trial) and is
undergoing further clinical trials [22, 23]. Ustekinumab was
generally well tolerated in these IBD patients [22, 23]. In the
long term, it remains to be determined whether an antibody
targeting solely IL-23 p19 will have a better eﬃcacy/safety
ratio than Ustekinumab in IBD patients [21–23].
In order to investigate a downstream component of the
IL-23 pathway, Takedatsu et al. determined whether a mAb
to the IL-23 receptor (IL-23R) attenuated indices of acute or
chronic-DSS-induced colitis in mice [16]. Interestingly, the
chronic phase of colitis was attenuated by treatment with the
IL-23mAbtoagreaterdegreethantheacutephaseofcolonic
inﬂammation [16]. Furthermore, the anticolitis eﬀects with
the IL-23 mAb seemed to be less dramatic than the eﬀects
with the mAb to TLA1 [16]. As suggested by the authors, it is
possible that neutralizing TL1A could induce more compre-
hensive eﬀects than just blocking downstream components
of the IL-23/IL-17 axis (Figure 1)[ 14–16]. Therefore, in
addition to aﬀecting IL-17 production (Figure 1), blocking
the IL-12/IFN-γ pathway by TL1A neutralization may also
be needed to eﬀectively treat the colonic inﬂammation
associatedwithhumanIBD[16].Interestingly,ithasrecently
been reported that, in CD patients, there is a population of
CD 161(+) CD4 T-cells which produce both IL-17 and IFN-
γ [24]. As a whole, these results emphasize the complexity
in the pathogenesis of IBD, involving multiple inﬂammatory
mediators. This complexity must be recognized within the
context of developing novel pharmacological approaches for
UC and CD.
4.IL-17
Elevated expression of IL-17 has been reported in the in-
ﬂamed intestine of patients with UC and CD [2, 24]. IL-
17, which is the prototypical cytokine produced by Th17
cells, plays a potential role in the ampliﬁcation of intestinal
inﬂammation.Speciﬁcally,IL-17stimulatesvariouscelltypes
(endothelial cells, myoﬁbroblasts, and epithelial cells) to
produce proinﬂammatory mediators that amplify intestinal
inﬂammation (Figure 1)[ 25, 26]. Therefore, it is interesting
that variable and somewhat contrasting results have been
obtained with approaches that inhibit the function of IL-17
in animal models of IBD [25–28]. These contrasting results
could be related to diﬀerent functions of IL-17A and IL-17F,
within the speciﬁc context of intestinal inﬂammation [25–
27]. In this regard, Yang and colleagues showed that murine
DSS-induced colitis was worsened in IL-17A knockout (KO)
mice but signiﬁcantly improved in IL-17F KO mice [27].
Furthermore, a protective role was also proposed for IL-17A
in a T-cell transfer model of colitis [26, 28]. In contrast,
Zhang and colleagues showed that acute TNBS-induced
colitis was attenuated in IL-17 receptor (IL-17R) KO mice, as
well as in animals treated with an IL-17 R:Fc fusion protein
[25]. It is probable that the IL-17 R KO mice would not
respondtoeitherIL-17AorIL-17F,suggestingthatinhibition
of both forms of IL-17 is needed for attenuation of colitis
[25].
Vidoﬂudimus (4SC-101) is a novel small molecule
inhibitor of dihydroorotate dehydrogenase (DHODH),
which is a key enzyme involved in pyrimidine (i.e., uridine
biosynthesis) in activated lymphocytes [4]. However, our
research group showed that Vidoﬂudimus inhibited IL-17
production in activated lymphocytes, even in the presence
of exogenous uridine. Our results suggested a pharmaco-
logical eﬀect that was independent of inhibiting DHODH
and T-cell proliferation [4]. Subsequently, we showed that
Vidoﬂudimus could inhibit IL-17 secretion in activated
splenocytes by inhibiting STAT3 and NF-κB-signaling path-
ways [29]. Importantly, Vidoﬂudimus attenuated various
parameters of acute TNBS-induced colitis in mice, including
IL-17 production [4]. Speciﬁcally, this anticolitis proﬁle was
associated with a reduction in the colonic expression of both
IL-17 A/A homodimers, as well as IL-17 F/A heterodimers
[4]. These results suggested that Vidoﬂudimus would be
an appropriate drug for use in patients with IBD. Indeed,
in a recent Phase II European clinical trial, Vidoﬂudimus
demonstrated a good eﬃcacy and safety proﬁle in patients
with IBD [30]. Because this small molecule compound
has the potential for inhibiting T-lymphocyte proliferation,
as well as inhibiting relevant IL-17A and IL-17F signal
transduction pathways, it is an interesting candidate for
future clinical studies.
Finally, with regard to IL-17 inhibition, AIN457 (Secuk-
inumab) is a human anti-IL-17A antibody that has been
developed by Novartis Healthcare [26] .B a s e do na no r a l
presentation at the 2011 Digestive Disease Week meeting,
it seems that recent clinical results in CD patients treated
with AIN457 have been negative. Speciﬁcally, Secukinumab-
treated patients did not show improvement in parameters of
disease [31]. At ﬁrst glance, these results seem to be coun-
terintuitive to the schematic pathways in Figure 1.H o w e v e r ,
plasma levels of IL-17F, as well as IL-17F production by
stimulated splenocytes, are elevated in IL-17A-deﬁcient mice
[32]. In this regard, the preclinical literature suggests that4 International Journal of Inﬂammation
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Figure 2: This ﬁgure shows three novel intracellular signaling pathways involved in the pathogenesis of IBD. Pathway 1: TNF-α
induces adhesion molecule expression in endothelial cells, as well as proinﬂammatory cytokine (IL-1β, IL-6) production by monocytes,
through a sphingosine kinase (SK), sphingosine-1-phosphate (S1P), nuclear factor-kappa B (NF-κB)-dependent pathway. Pathway 2: upon
stimulation of cells with proinﬂammatory cytokines (IFN-γ,T N F - α,a n dI L - 1 β), constitutive proteasome subunits are converted to the
immunoproteasomesubunitsβ1i(LMP2),β2i(LMP10,MECL-1),andβ5i(LMP7)[38–40].Functionally,immunoproteasomesubunitsplay
a role in NF-κB signaling. Pathway 3: dual activation of NF-κB and STAT3 pathways controls the expression of IL-17. As shown in this ﬁgure,
crosstalk between these three pathways occurs, thereby promoting intestinal inﬂammation. Speciﬁc components of these pathways such
as sphingosine kinase (SK), immunoproteasome subunits (LMP2, LMP7, and LMP10), and interactions between NF-κB/STAT3 represent
possible pharmacological targets for IBD. In the ﬁgure: LMP is low molecular mass polypeptide (2, 5, or 10); JAK2 is Janus Kinase 2; PI3K is
phosphoinositide-3 kinase; AKT1 is Alpha serine/threonine-protein kinase.
speciﬁcally inhibiting IL-17F, and/or inhibiting both IL-17
A and IL-17F, may be necessary to achieve good anticolitis
actions [4, 25, 27].
5.NovelIntracellularSignalingTargetsfor IBD
Figure 2 shows three intracellular signaling pathways that are
potentially involved in the pathogenesis of IBD: (1) altered
sphingolipid metabolism, whereby the enzyme sphingosine
kinase (SK) appears to play a critical role in signaling
by TNF-α [9–11], (2) upregulation of immunoproteasome
subunits by proinﬂammatory cytokines, which downstream
is connected to activation of the NF-κB signal transduction
system [5–8, 33–35], and (3) dual activation of NF-κB
and STAT3 signal pathways by cytokines, which results in
enhanced IL-17 production by leukocytes [29, 36, 37]. These
pathwaysaresummarizedinFigure 2.Interestingly,asshown
in this ﬁgure, crosstalk between inﬂammatory pathways
occurs, which likely promotes intestinal inﬂammation.
Based on the pathways outlined in Figure 2, this section
of the review will speciﬁcally focus on three pharmacological
targets for IBD: (1) inhibition of SK, (2) inhibiting speciﬁc
catalytic subunits of the immunoproteasome, and (3) mod-
ulating NF-κB/STAT3 interactions.
6. SK Inhibition
SK is involved in the conversion of sphingosine to sphingo-
sine-1-phosphate (S1P) [9–11]. Importantly, SK exists
as two isoforms (SK1 and SK2), with diverse biological
functions, which have been reviewed elsewhere [41, 42]. A
critical step in the mechanism of action for TNF-α includes
the activation of SK [9–11, 41, 42]. Of critical relevance
to this review, SK signals downstream through activation
of the transcription factor NF-κB( Figure 2,p a t h w a y1 ) .
Speciﬁcally, in vitro studies have shown that TNF-α induces
adhesion molecule expression in endothelial cells, as well
as proinﬂammatory cytokine (IL-1β,I L - 6 )p r o d u c t i o nb yInternational Journal of Inﬂammation 5
monocytes, through an SK-SIP-NF-κB-dependent pathway
(Figure 2)[ 9, 43, 44]. Recent results have shown that SK1
expression was increased in colonic tissue samples from
patients with UC [11]. The potential role that SK plays in
the generation of proinﬂammatory molecules relevant to the
pathogenesis of IBD has prompted investigators to evaluate
whether SK inhibition can eﬀectively attenuate intestinal
inﬂammation.
Snider et al. showed that DSS-induced colitis was less
severe in SK-1-deﬁcient (SK1−/−) mice compared to wild-
type control mice [11]. From a pharmacodynamic stand-
point, intestinal SK1 mRNA expression, as well as SK
activity (generation of S1P) were both attenuated in SK1-
deﬁcient mice. These results suggest that speciﬁc inhibition
of SK1 may represent a valid pharmacological approach for
IBD [11]. Maines and colleagues showed that treatment of
mice with ABC249640 (a selective small molecule inhibitor
of SK2) eﬀectively attenuated parameters of murine DSS-
induced colitis, as well as TNBS-induced colitis in mice and
rats [9, 10]. Treatment of mice with ABC294640 resulted
in reduced colonic S1P levels, as well as decreased levels of
proinﬂammatory cytokines (IL-1β,I L - 6 ,T N F - α,a n dI F N - γ)
[9, 10]. Interestingly, these investigators found that this small
molecule inhibitor also potently inhibited TNF-α-induced
NF-κBactivationinvitro[9].Asawhole,theseresultssuggest
that inhibiting SK2 may also represent a good therapeutic
approach for IBD [9, 10]. Since SK1 and SK2 are reported
to have diﬀerent biological actions on cellular proliferation
and apoptosis [42, 43], it remains to be determined as to
which SK isoform represents the best pharmacological tar-
get for IBD [9–11]. Nevertheless, targeting the SK pathway
(Figure 2) seems to be a rational therapeutic approach for
IBD.
7. Inhibition of Immunoproteasome Subunits
The constitutive 20S proteasome has a cylindrical structure
consisting of three catalytic subunits (β1, β2, and β5). Upon
stimulation of cells with proinﬂammatory cytokines (IFN-γ
and TNF-α), these constitutive subunits are converted to the
immunoproteasome subunits β1i (LMP2), β2i (LMP10 or
MECL-1), and β5i (LMP7) [38–40]. Functionally, immuno-
proteasome subunits play a role in MHC class I antigen
p r e s e n t a t i o n ,a sw e l la sN F - κB signaling [40, 45–47].
Over the past ﬁve years, several research groups (includ-
ingourown)havesuggestedapotentialrolefortheimmuno-
proteasome subunits in the pathogenesis of both murine
colitis and human IBD [5–8, 33–35]. We showed enhanced
expression of the LMP2 (low molecular mass polypeptide
2) subunit in patients with active IBD, particularly in CD
patients. Interestingly, LMP2 was also upregulated in areas
of the intestine devoid of macroscopic disease [5]. Generally,
our results were conﬁrmed by other investigators, who
showed signiﬁcantly enhanced levels of LMP2, LMP7, and
LMP10 in CD patients [33–35, 48]. Importantly, in patients
with CD, upregulation of the NF-κB signal transduction
system was observed in the inﬂamed intestinal mucosa
[33].
Using LMP2 knockout mice, we showed that various
parameters of DSS-induced colitis (including colonic IL-
1β) were improved compared to WT control mice [6].
Schmidt and colleagues found that parameters of DSS-
induced colitis were also attenuated in LMP7-deﬁcient-mice
[8].Inthesemice,therewasdiminishedactivationoftheNF-
κB signal transduction system, resulting in less expansion
of Th1 and Th17 T-cells [8]. Basler et al. extended these
ﬁndings. They showed that mice deﬁcient in any of the
immunoproteasome subunits (LMP2, LMP7, and MECL-1)
had signiﬁcant improvements in multiple indices of DSS-
induced colitis [7]. Interestingly, signiﬁcantly reduced levels
of Th1 and Th17 cytokines were found in the LMP-deﬁcient
mice [7]. As a whole, these data suggest that targeting
speciﬁc LMP subunits may represent a novel and eﬀective
pharmacological strategy for IBD (Figure 2,p a t h w a y2 ) .
From a practical standpoint, targeting speciﬁc LMP
subunits might best be done by novel chemical inhibitors.
Importantly, it has already been shown that treatment with
a selective inhibitor of LMP7 (PR-957) strongly suppressed
murine DSS-induced colitis [8]. A drug development strat-
egy, using speciﬁc LMP proteasome inhibitors (like PR-957),
may provide good eﬃcacy in IBD without the side eﬀects of
nonselective inhibitors like bortezomib, which also inhibits
the constitutive subunits of the proteasome [5–8]. A speciﬁc
chemical inhibitor of LMP2, designated as UK-101, has also
been developed by a research group at the University of
Kentucky [49]. This compound should also be tested in
animal models of IBD. Finally, selective immunoproteasome
inhibitors need to be tested in other colitis models, beyond
the testing that has already been completed in the DSS model
[8]. Results from these preclinical studies should allow the
identiﬁcation of optimal compound(s) to be progressed into
clinical trials for IBD.
8. Inhibition of NF-κB/STAT3-Signaling
Pathways
It has been well documented in the literature that the NF-
κB pathway, as well as the STAT3 pathway, could be critically
involved in the pathogenesis of IBD. Importantly, these
papers delineate the roles of these pathways in mediating
intestinal inﬂammation. This literature also points out
potential drawbacks of inhibiting NF-κB in epithelial cells, as
well as blocking STAT3 in epithelial cells and innate immune
cells [50–56].
Recently, intriguing information has also been published
regarding dual activation of NF-κβ and STAT3 pathways
in pathological conditions such as hepatic inﬂammation
and cancer [12, 57, 58]. It is evident from Figure 2 that
NF-κB and STAT3 dually control the expression of some
target genes (e.g., IL-17), thereby facilitating inﬂammation
[12, 55, 57, 58]. Speciﬁcally, it was shown that the canonical
NF-κB pathway (involving IκB-α degradation) and the
STAT3pathway(involvingJAK2,PI3K,andAKT1activation)
are both activated by splenic-derived T-cell populations,
following dual stimulation with IL-1β plus IL-23 (Figure 2)
[36, 37]. Sutton and colleagues demonstrated that STAT36 International Journal of Inﬂammation
and NF-κB pathways mediated IL-17 production from γδ T-
cells [37, 59]. Subsequently, these investigators reported that
both γδ and CD4+ T-cells (via IL-17 production) promoted
experimental autoimmune encephalomyelitis (EAE) in mice
[59].
It is probable that interactions between the NF-κBa n d
STAT3 pathways could also contribute to the pathogenesis
of intestinal inﬂammation/IBD (Figure 2,p a t h w a y3 )[ 12].
Indeed, activation of these pathways was described in
conjunction with DSS-induced colitis in mice, as well as
in murine TNBS-induced colitis [29, 60]. From a phar-
macological development standpoint, there are two key
questions that remain to be answered. (1) Are there any
small molecule inhibitors that would be good candidates to
inhibit interactions between NF-κB and STAT3? (2) Would
inhibition of these pathways be beneﬁcial?
Indeed, Youn et al. showed that treatment of mice with
two plant-derived polyphenols (resveratrol and piceatannol)
resulted in the attenuation of DSS-induced colonic inﬂam-
m a t i o n ,a sw e l la sd o w n r e g u l a t i o no fa c t i v a t e dN F - κBa n d
STAT3 [60]. More recently, we have found that treatment
with Vidoﬂudimus attenuated the activation of STAT3 and
NF-κB pathways, as well as IL-17 production, in murine
splenocytes and TNBS-induced colitis [5, 29]. The anticolitis
eﬀects that were observed with these chemical compounds
are encouraging. However, resveratrol and piceatannol have
antioxidant properties, while Vidoﬂudimus can inhibit T-
cell proliferation [5, 29, 60]. Therefore, further preclinical
c o l i t i ss t u d i e sn e e dt ob ep e r f o r m e dw i t hm o r es p e c i ﬁ c
dual inhibitors of NF-κB and STAT3, in order to gauge the
clinical potential of this pharmacological approach for IBD.
In this regard, a triterpenoid C28 methyl ester derivative
(CDDOmethylester)isaninhibitorofSTAT3(bypreventing
STAT3 phosphorylation), as well as an inhibitor of NF-κB
(by inhibiting IκB kinase and downstream components of
this signal transduction pathway) [61, 62]. Moreover, triter-
penoids were eﬀective in preclinical models of pancreatic
cancer and cystic ﬁbrosis lung disease [63, 64]. Therefore,
CDDO methyl ester, or similar compounds, would be good
candidates for testing in preclinical models of IBD.
In summary, all of the potential pharmacological targets
(Figures 1 and 2) discussed in this review are upregulated in
patients with IBD. Therefore, based on the preponderance of
current data, several good opportunities exist for pharmaco-
logical inhibition of key components in the IL-23 and IL-17
pathways (Figure 1). These approaches include (1) speciﬁc
mAb’s to TL1A, (2) IL-17 R:Fc fusion proteins, (3) speciﬁc
antibodies to IL-17F, and (4) small molecule inhibitors
like Vidoﬂudimus. Also, other potential opportunities for
targeted drug development in IBD include speciﬁc chemical
inhibitors of SK, speciﬁc small molecule inhibitors directed
against catalytic subunits of the immunoproteasome, and
dual inhibitors of the STAT3 and NF-κB signal transduction
systems (Figure 2).
In the near future, critically designed preclinical studies
are still needed to determine which of these pharmacological
approaches will provide drugs with the best eﬃcacy and
safety proﬁles for entrance into clinical trials. Subsequently,
well-designed clinical trials are needed to determine the
speciﬁc pharmacological approaches that will prove to be
most successful in patients with IBD.
References
[1] D. Q. Shih and S. R. Targan, “Insights into IBD pathogenesis,”
Current Gastroenterology Reports, vol. 11, no. 6, pp. 473–480,
2009.
[2] M. Nagahori, Y. Nemoto, and M. Watanabe, “Pathogenesis of
inﬂammatoryboweldiseases,”IntestRes,vol.8,pp.9–17,2010.
[3] J. K. Triantaﬁllidis, E. Merikas, and F. Georgopoulos, “Current
and emerging drugs for the treatment of inﬂammatory bowel
disease,” Drug Design, Development and Therapy, vol. 5, pp.
185–210, 2011.
[4] L. R. Fitzpatrick, L. Deml, C. Hofmann et al., “4SC-101, a
novel immunosuppressive drug, inhibits IL-17 and attenuates
colitis in two murine models of inﬂammatory bowel disease,”
Inﬂammatory Bowel Diseases, vol. 16, no. 10, pp. 1763–1777,
2010.
[ 5 ]L .R .F i t z p a t r i c k ,J .S .S m a l l ,L .S .P o r i t z ,K .J .M c K e n n a ,
and W. A. Koltun, “Enhanced intestinal expression of the
proteasome subunit low molecular mass polypeptide 2 in
patients with inﬂammatory bowel disease,” Diseases of the
Colon and Rectum, vol. 50, no. 3, pp. 337–350, 2007.
[ 6 ]L .R .F i t z p a t r i c k ,V .K h a r e ,J .S .S m a l l ,a n dW .A .K o l t u n ,
“Dextran sulfate sodium-induced colitis is associated with en-
hanced low molecular mass polypeptide 2 (LMP2) expression
and is attenuated in LMP2 knockout mice,” Digestive Diseases
and Sciences, vol. 51, no. 7, pp. 1269–1276, 2006.
[ 7 ]M .B a s l e r ,M .D a j e e ,C .M o l l ,M .G r o e t t r u p ,a n dC .J .K i r k ,
“Prevention of experimental colitis by a selective inhibitor of
the immunoproteasome,” Journal of Immunology, vol. 185, no.
1, pp. 634–641, 2010.
[8] N. Schmidt, E. Gonzalez, A. Visekruna et al., “Targeting the
proteasome: partial inhibition of the proteasome by borte-
zomib or deletion of the immunosubunit LMP7 attenuates
experimental colitis,” Gut, vol. 59, no. 7, pp. 896–906, 2010.
[9] L.W.Maines,L.R.Fitzpatrick,K.J.Frenchetal.,“Suppression
of ulcerative colitis in mice by orally available inhibitors of
sphingosine kinase,” Digestive Diseases and Sciences, vol. 53,
no. 4, pp. 997–1012, 2008.
[10] L. W. Maines, L. R. Fitzpatrick, C. L. Green, Y. Zhuang, and
C. D. Smith, “Eﬃcacy of a novel sphingosine kinase inhibitor
in experimental Crohn’s disease,” Inﬂammopharmacology, vol.
18, no. 2, pp. 73–85, 2010.
[11] A. J. Snider, T. Kawamori, S. G. Bradshaw et al., “A role
for sphingosine kinase 1 in dextran sulfate sodium-induced
colitis,” FASEB Journal, vol. 23, no. 1, pp. 143–152, 2009.
[12] S. Danese and A. Mantovani, “Inﬂammatory bowel disease
and intestinal cancer: a paradigm of the Yin-Yang interplay
between inﬂammation and cancer,” Oncogene, vol. 29, no. 23,
pp. 3313–3323, 2010.
[13] D. Q. Shih, L. Y. Kwan, V. Chavez et al., “Microbial induc-
tion of inﬂammatory bowel disease associated gene TL1A
(TNFSF15) in antigen presenting cells,” European Journal of
Immunology, vol. 39, no. 11, pp. 3239–3250, 2009.
[14] D. Q. Shih, K. S. Michelsen, and R. J. Barrett, “Insights into
TL1A and IBD pathogenesis,” in Advances in TNF Family
Research,D .W a l l a c h ,A .K o v a l e n k o ,a n dM .F e l d m a n n ,E d s . ,
pp. 279–288, Springer, New York, NY, USA, 2011.
[15] B. P. Pappu, A. Borodovsky, T. S. Zheng et al., “TL1A-DR3
interaction regulates Th17 cell function and Th17-mediatedInternational Journal of Inﬂammation 7
autoimmune disease,” Journal of Experimental Medicine, vol.
205, no. 5, pp. 1049–1062, 2008.
[16] H.Takedatsu,K.S.Michelsen,B.Weietal.,“TL1A(TNFSF15)
regulates the development of chronic colitis by modulating
both T-helper 1 and T-helper 17 activation,” Gastroenterology,
vol. 135, no. 2, pp. 552–e2, 2008.
[17] F. Meylan, Y.-J. Song, I. Fuss et al., “The TNF-family cytokine
TL1A drives IL-13-dependent small intestinal inﬂammation,”
Mucosal Immunology, vol. 4, no. 2, pp. 172–185, 2011.
[18] V. Y. Taraban, T. J. Slebioda, J. E. Willoughby et al., “Sustained
TL1A expression modulates eﬀector and regulatory T-cell
responsesanddrivesintestinalgobletcellhyperplasia,” Mucos-
al Immunology, vol. 4, no. 2, pp. 186–196, 2011.
[19] G. Bamias, M. Mishina, M. Nyce et al., “Role of TL1A and its
receptor DR3 in two models of chronic murine ileitis,” Pro-
ceedingsoftheNationalAcademyofSciencesoftheUnitedStates
of America, vol. 103, no. 22, pp. 8441–8446, 2006.
[20] D. McGovern and F. Powrie, “The IL23 axis plays a key role in
the pathogenesis of IBD,” Gut, vol. 56, no. 10, pp. 1333–1336,
2007.
[21] C. O. Elson, Y. Cong, C. T. Weaver et al., “Monoclonal anti-
interleukin23reversesactivecolitisinaTcell-mediatedmodel
in mice,” Gastroenterology, vol. 132, no. 7, pp. 2359–2370,
2007.
[22] M. Elliott, J. Benson, M. Blank et al., “Ustekinumab: lessons
learned from targeting interleukin-1223p40 in immune-
mediateddiseases,”AnnalsoftheNewYorkAcademyofSciences,
vol. 1182, pp. 97–110, 2009.
[23] J.M.Benson,C.W.Sachs,G.Treacyetal.,“Therapeutictarget-
ing of the IL-12/23 pathways: generation and characterization
of ustekinumab,” Nature Biotechnology, vol. 29, no. 7, pp. 615–
624, 2011.
[24] M. A. Kleinschek, K. Boniface, S. Sadekova et al., “Circulating
and gut-resident human Th17 cells express CD161 and
promote intestinal inﬂammation,” Journal of Experimental
Medicine, vol. 206, no. 3, pp. 525–534, 2009.
[25] Z. Zhang, M. Zheng, J. Bindas, P. Schwarzenberger, and J. K.
Kolls, “Critical role of IL-17 receptor signaling in acute TNBS-
induced colitis,” Inﬂammatory Bowel Diseases, vol. 12, no. 5,
pp. 382–388, 2006.
[26] A. Strze ¸pa and M. Szczepanik, “IL-17-expressing cells as a
potential therapeutic target for treatment of immunological
disorders,” Pharmacological Reports, vol. 63, no. 1, pp. 30–44,
2011.
[27] X. O. Yang, H. C. Seon, H. Park et al., “Regulation of in-
ﬂammatory responses by IL-17F,” Journal of Experimental
Medicine, vol. 205, no. 5, pp. 1063–1075, 2008.
[28] W. O’Connor, M. Kamanaka, C. J. Booth et al., “A protective
function for interleukin 17A in T cell-mediated intestinal
inﬂammation,” Nature Immunology, vol. 10, no. 6, pp. 603–
609, 2009.
[29] L. R. Fitzpatrick, J. S. Small, and A. Ammendola, “Inhibi-
tion of IL-17 release by the novel anti-inﬂammatory drug
vidoﬂudimus involves attenuation of STAT3 and NF-kappa B
pathways in murine splenocytes and hapten induced colitis,”
Gastroenterology, vol. 140, p. S 837, 2011.
[30] K. R. Herrlinger, M. Diculescu, K. Fellermann et al., “Eﬃcacy,
safety, and tolerability of vidoﬂudimus in patients with
inﬂammatory bowel disease: the entrance study,” Gastroen-
terology, vol. 140, pp. S588–S589, 2011.
[31] J. F. Colombel, “No response to anti-TNFs; novel agents in the
near future,” in Proceedings of the DDW Meeting,C o n t e m p o -
rary Therapeutic Dilemmas in IBD, Chicago, Ill, USA, 2011.
[32] S. Von Vietinghoﬀ and K. Ley, “IL-17A controls IL-17F pro-
duction and maintains blood neutrophil counts in mice,”
Journal of Immunology, vol. 183, no. 2, pp. 865–873, 2009.
[33] A. Visekruna, T. Joeris, D. Seidel et al., “Proteasome-mediated
degradation of IκBα and processing of p105 in Crohn disease
and ulcerative colitis,” Journal of Clinical Investigation, vol.
116, no. 12, pp. 3195–3203, 2006.
[34] A. Visekruna, T. Joeris, N. Schmidt et al., “Comparative ex-
pression analysis and characterization of 20S proteasomes in
human intestinal tissues: the proteasome pattern as diagnostic
tool for IBD patients,” Inﬂammatory Bowel Diseases, vol. 15,
no. 4, pp. 526–533, 2009.
[35] A. Visekruna, N. Slavova, S. Dullat et al., “Expression of cata-
lytic proteasome subunits in the gut of patients with Crohn’s
disease,” International Journal of Colorectal Disease, vol. 24, no.
10, pp. 1133–1139, 2009.
[ 3 6 ]M .L .C h o ,J .W .K a n g ,Y .M .M o o ne ta l . ,“ S T A T 3a n dN F - κB
signal pathway is required for IL-23-mediated IL-17 produc-
tion in spontaneous arthritis animal model IL-1 receptor
antagonist-deﬁcient mice,” Journal of Immunology, vol. 176,
no. 9, pp. 5652–5661, 2006.
[37] C. Sutton, C. Brereton, B. Keogh, K. H. G. Mills, and E. C.
Lavelle, “A crucial role for interleukin (IL)-1 in the induction
of IL-17-producing T cells that mediate autoimmune enceph-
alomyelitis,” Journal of Experimental Medicine, vol. 203, no. 7,
pp. 1685–1691, 2006.
[38] S. Scheﬄer, U. Kuckelkorn, K. Egerer et al., “Autoimmune
reactivity against the 20S-proteasome includes immunosub-
units LMP2 (β1i), MECL1 (β2i) and LMP7 (β5i),” Rheumatol-
ogy, vol. 47, no. 5, pp. 622–626, 2008.
[39] M. Aki, N. Shimbara, M. Takashina et al., “Interferon-γ indu-
ces diﬀerent subunit organizations and functional diversity of
proteasomes,” Journal of Biochemistry, vol. 115, no. 2, pp. 257–
269, 1994.
[40] T. Hayashi and D. Faustman, “Essential role of human
leukocyte antigen-encoded proteasome subunits in NF-κB
activation and prevention of tumor necrosis factor-α-induced
apoptosis,” Journal of Biological Chemistry, vol. 275, no. 7, pp.
5238–5247, 2000.
[41] M. Maceyka, H. Sankala, N. C. Hait et al., “SphK1 and SphK2,
sphingosine kinase isoenzymes with opposing functions in
sphingolipid metabolism,” Journal of Biological Chemistry, vol.
280, no. 44, pp. 37118–37129, 2005.
[42] J. S. Karliner, “Sphingosine kinase regulation and cardiopro-
tection,” Cardiovascular Research, vol. 82, no. 2, pp. 184–192,
2009.
[43] P. Xia, J. R. Gamble, K. A. Rye et al., “Tumor necrosis factor-
α induces adhesion molecule expression through the sphin-
gosine kinase pathway,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 95, no. 24, pp.
14196–14201, 1998.
[44] L. Zhi, B. P. Leung, and A. J. Melendez, “Sphingosine kinase
1 regulates pro-inﬂammatory responses triggered by TNFα
in primary human monocytes,” Journal of Cellular Physiology,
vol. 208, no. 1, pp. 109–115, 2006.
[45] J. D. Mountz, “Signiﬁcance of increased circulating protea-
some in autoimmune disease,” Journal of Rheumatology, vol.
29, no. 10, pp. 2027–2030, 2002.
[46] M. Groettrup and G. Schmidtke, “Selective proteasome in-
hibitors: modulators of antigen presentation?” Drug Discovery
Today, vol. 4, no. 2, pp. 63–71, 1999.
[47] M. Groettrup, S. Khan, K. Schwarz, and G. Schmidtke, “In-
terferon-γ inducible exchanges of 20S proteasome active site
subunits: why?” Biochimie, vol. 83, no. 3-4, pp. 367–372, 2001.8 International Journal of Inﬂammation
[48] M. Co¨ eﬃer, R. Gloro, N. Boukhettala et al., “Increased pro-
teasome-mediated degradation of occludin in irritable bowel
syndrome,” American Journal of Gastroenterology, vol. 105, no.
5, pp. 1181–1188, 2010.
[49] Y.K.Ho,P.Bargagna-Mohan,M.Wehenkel,R.Mohan,andK.
B. Kim, “LMP2-Speciﬁc inhibitors: chemical genetic tools for
proteasome biology,” Chemistry and Biology, vol. 14, no. 4, pp.
419–430, 2007.
[ 5 0 ]I .A t r e y a ,R .A t r e y a ,a n dM .F .N e u r a t h ,“ N F - κB in inﬂamma-
tory bowel disease,” Journal of Internal Medicine, vol. 263, no.
6, pp. 591–596, 2008.
[51] C. Jobin, “Nf-kappa B signaling cascade and IBD: turn it
down?” Inﬂammatory Bowel Diseases, vol. 14, supplement 2,
pp. S108–S109, 2008.
[52] K. Sugimoto, “Role of STAT3 in inﬂammatory bowel disease,”
World Journal of Gastroenterology, vol. 14, no. 33, pp. 5110–
5114, 2008.
[53] K. Mitsuyama, S. Matsumoto, J. Masuda et al., “Therapeutic
strategies for targeting the IL-6/STAT3 cytokine signaling
pathway in inﬂammatory bowel disease,” Anticancer Research,
vol. 27, no. 6 A, pp. 3749–3756, 2007.
[54] J.WeiandJ.Feng,“Signalingpathwaysassociatedwithinﬂam-
matory bowel disease,” Recent Patents on Inﬂammation and
Allergy Drug Discovery, vol. 4, no. 2, pp. 105–117, 2010.
[55] J.KurtovicandI.Segal,“Recentadvancesinbiologicaltherapy
for inﬂammatory bowel disease,” Tropical Gastroenterology,
vol. 25, no. 1, pp. 9–14, 2004.
[56] C. Neufert, G. Pickert, Y. Zheng et al., “Activation of epithelial
STAT3 regulates intestinal homeostasis,” Cell Cycle, vol. 9, no.
4, pp. 652–655, 2010.
[57] S. I. Grivennikov and M. Karin, “Dangerous liaisons: STAT3
and NF-κB collaboration and crosstalk in cancer,” Cytokine
and Growth Factor Reviews, vol. 21, no. 1, pp. 11–19, 2010.
[58] G. He and M. Karin, “NF-κB and STAT3-key players in liver
inﬂammation and cancer,” Cell Research,v o l .2 1 ,n o .1 ,p p .
159–168, 2011.
[ 5 9 ]C .E .S u t t o n ,S .J .L a l o r ,C .M .S w e e n e y ,C .F .B r e r e t o n ,E .C .
Lavelle, and K. H. G. Mills, “Interleukin-1 and IL-23 induce
innate IL-17 production from γδ T cells, amplifying Th17
responses and autoimmunity,” Immunity,v o l .3 1 ,n o .2 ,p p .
331–341, 2009.
[60] J. Youn, J. S. Lee, H. K. Na, J. K. Kundu, and Y. J. Surh,
“ResveratrolandpiceatannolinhibitiNOSexpressionandNF-
kappaB activation in dextran sulfate sodium-induced mouse
colitis,”NutritionandCancer,vol.61,no.6,pp.847–854,2009.
[61] R. Ahmad, D. Raina, C. Meyer, and D. Kufe, “Triterpenoid
CDDO-methyl ester inhibits the Janus-activated kinase-1
(JAK1)→signal transducer and activator of transcription-3
(STAT3) pathway by direct inhibition of JAK1 and STAT3,”
Cancer Research, vol. 68, no. 8, pp. 2920–2926, 2008.
[62] S. Shishodia, G. Sethi, M. Konopleva, M. Andreeﬀ, and B. B.
Aggarwal, “A synthetic triterpenoid, CDDO-Me, inhibits IκBα
kinase and enhances apoptosis induced by TNF and chemo-
therapeutic agents through down-regulation of expression of
nuclear factor κB-regulated gene products in human leukemic
cells,” Clinical Cancer Research, vol. 12, no. 6, pp. 1828–1838,
2006.
[63] K. T. Liby, D. B. Royce, R. Risingsong et al., “Synthetic trit-
erpenoids prolong survival in a transgenic mouse model of
pancreatic cancer,” Cancer Prevention Research, vol. 3, no. 11,
pp. 1427–1434, 2011.
[ 6 4 ]D .P .N i c h o l s ,A .G .Z i a d y ,S .L .S h a n k ,J .F .E a s t m a n ,a n d
P. B. Davis, “The triterpenoid CDDO limits inﬂammation in
preclinical models of cystic ﬁbrosis lung disease,” American
Journal of Physiology, vol. 297, no. 5, pp. L828–L836, 2009.